Amgen Inc. stock (US0311621009): obesity data, Horizon deal and pipeline put focus back on the biotech heavyweight

Amgen is back in the spotlight after new obesity drug data, ongoing integration of Horizon Therapeutics and a solid start to 2026. What is driving the biotech group’s revenue base – and what risks should US retail investors keep in mind?

Amgen Inc. has moved back into focus for biotech investors in 2026 as the company advances its experimental obesity drug AMG 133 (MariTide), continues integrating the acquired rare-disease specialist Horizon Therapeutics, and reports solid growth from its core oncology and inflammation portfolio, according to the company’s latest investor materials and earnings updates published in early 2026 Amgen investor information as of 02/2026. The interplay between mature biologics, new launches and a potential entry into the high-profile obesity market is shaping sentiment around the stock, which trades on Nasdaq under the ticker AMGN Nasdaq data as of 02/2026.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biotechnology, pharmaceuticals
• Headquarters/country: Thousand Oaks, California, USA
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oncology, inflammation, bone health, cardiovascular and rare diseases
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen is one of the largest pure-play biotechnology groups worldwide, focusing on the discovery, development and commercialization of human therapeutics, particularly biologic drugs such as monoclonal antibodies and recombinant proteins. The company’s portfolio spans oncology, inflammation, bone health, cardiovascular disease, nephrology and, increasingly, rare diseases, according to its latest company profile and filings Amgen Form 10-K as of 02/2025. This diversified therapeutic focus aims to mitigate dependence on any single product while leveraging common scientific and commercial capabilities across franchises.

The group’s business model rests on high-margin branded medicines backed by robust intellectual property, supported by a growing contribution from biosimilars. Amgen invests heavily in research and development to expand its pipeline, while also using business development and acquisitions to access external innovation, as underlined by the purchase of Horizon Therapeutics, which was completed in 2023 and continues to influence the company’s revenue mix and strategic direction Amgen press release as of 10/06/2023. This combination of internal R&D and deal making is typical for large-cap US biotech companies seeking to sustain growth beyond patent cliffs.

From a commercial standpoint, Amgen’s sales model relies on global distribution and reimbursement negotiations with public and private payers, primarily in the United States and Europe. The company’s drugs are largely prescription-only specialty therapies administered in hospitals, infusion centers or via self-injection at home, which requires dedicated field forces, medical science liaisons and patient support programs. Pricing, formulary access and treatment guidelines are therefore critical levers for maintaining and growing market share in each indication, as Amgen regularly emphasizes in its risk disclosures and management commentary Amgen Form 10-K as of 02/2025.

Main revenue and product drivers for Amgen Inc.

Amgen’s revenue base is spread across multiple key products. Longstanding blockbusters such as Enbrel for inflammatory diseases, Prolia and Xgeva for bone health and cancer-related bone complications, and Aranesp for anemia have historically contributed significant sales, although some of these medicines face slowing growth due to competition and payer pressure. Newer products, including the migraine drug Aimovig, the cardiovascular therapy Repatha, and oncology agents like Kyprolis and Blincyto, are intended to offset these headwinds and support medium-term growth, according to the company’s 2024 and 2025 reporting Amgen press release as of 02/06/2025.

The acquisition of Horizon Therapeutics has added a portfolio of rare disease and autoimmune products, notably Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout. These assets expose Amgen more directly to specialty physician segments like rheumatology and ophthalmology and deepen its presence in diseases with high unmet need but relatively small patient populations. While such drugs can support attractive pricing and margins, they also carry concentrated risk if a single product underperforms or faces competitive pressure, as management has highlighted when discussing integration priorities and pipeline synergies Amgen investor update as of 10/2023.

Another pillar of Amgen’s revenue strategy is biosimilars. The company markets biosimilar versions of blockbuster biologics developed by other pharmaceutical firms, allowing it to tap into large markets such as oncology and chronic inflammatory diseases with more affordable alternatives. Biosimilars typically offer lower prices than originator drugs but can still be profitable when produced at scale. Amgen’s biosimilar portfolio includes products targeting molecules such as adalimumab and bevacizumab, and management sees this business as both a growth driver and a hedge against price erosion in its own biologic franchises Amgen press release as of 08/2025.

Looking ahead, investor attention has increasingly shifted to Amgen’s obesity candidate AMG 133, also known as MariTide. Early clinical data have suggested meaningful weight loss with potential for less frequent dosing compared with some existing GLP-1 receptor agonists, according to data presented at medical meetings and summarized in company communications Amgen press release as of 11/05/2024. While the program remains in development and faces intense competition from larger incumbents in the obesity space, it illustrates Amgen’s ambition to participate in one of the fastest-growing therapeutic markets in global pharmaceuticals.

Industry trends and competitive position

Amgen operates in a dynamic environment in which large biopharma companies compete aggressively across oncology, immunology, cardiovascular disease and, more recently, metabolic disorders including obesity. Competition comes from US peers such as AbbVie, Gilead Sciences, Bristol Myers Squibb and Pfizer, as well as European players like Novartis and Roche. In many indications, Amgen’s therapies face not only other branded drugs but also biosimilars and generics, which tend to put pressure on pricing and market share over time, a trend the company regularly flags in its filings Amgen Form 10-K as of 02/2025.

Biosimilar adoption is itself a major industry trend. As healthcare systems seek to manage costs, payers often favor biosimilars where available, especially in oncology and chronic inflammatory diseases. Amgen is positioned on both sides of this dynamic: its historic blockbusters are exposed to biosimilar competition, while its own biosimilar offerings aim to capture share from rival originator products. This dual role requires careful portfolio management, as the company balances investing in innovative first-in-class or best-in-class drugs with scaling up biosimilar manufacturing and commercialization capabilities, a strategy management has discussed across recent capital markets events Amgen events and presentations as of 2025.

Another structural trend is the growing importance of real-world evidence, personalized medicine and biomarker-driven treatment decisions. Oncology drugs, for example, often target specific genetic mutations or expression profiles, and payers increasingly expect data demonstrating benefits in clearly defined patient subgroups. Amgen invests in companion diagnostics and registries to strengthen its value proposition for drugs like Blincyto and Lumakras, while also engaging with regulators and payers on outcome-based reimbursement models, according to its scientific publications and policy statements Amgen press release as of 06/2024.

Why Amgen Inc. matters for US investors

For US retail investors, Amgen represents exposure to the large-cap biotechnology segment, which combines pharmaceutical-style cash flows with biotechnology-style innovation risk. The stock is part of major US equity indices, making it a widely followed name among institutional and individual investors. As a mature biotech with diversified revenues and a long operating history, Amgen differs from early-stage biotech companies that often depend on a small number of pre-commercial assets and face binary outcomes around clinical trial readouts, a distinction that many portfolio managers emphasize when discussing risk profiles in the healthcare sector Amgen news overview as of 2025.

The company’s cash generation and shareholder-return policies, including dividends and share repurchases, have historically played an important role in its investment case. While buyback activity and payout levels can vary over time depending on capital allocation priorities such as acquisitions and R&D, Amgen has long communicated a commitment to returning capital to shareholders, subject to business conditions and regulatory constraints, according to its annual reports and investor presentations Amgen Form 10-K as of 02/2025. For US investors seeking healthcare exposure, the stock therefore offers a mix of income potential and pipeline-driven upside, alongside the usual volatility associated with drug development and reimbursement decisions.

Conclusion

Amgen Inc. stands at an interesting juncture: established blockbusters and a broad portfolio continue to generate substantial cash flows, while acquisitions such as Horizon Therapeutics and pipeline programs like the obesity candidate MariTide are intended to open new growth avenues. At the same time, the company must navigate pricing pressure, biosimilar competition, evolving regulatory requirements and the inherent uncertainty of clinical development, all of which can influence earnings trajectories and investor sentiment. For US investors, the stock offers exposure to a leading biotechnology name with a combination of mature products and innovation-driven optionality, but also the typical sector-specific risks tied to reimbursement, competition and scientific outcomes. As always, individual investment decisions depend on personal risk tolerance, portfolio context and time horizon.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.